Sun Pharma

Buy Sun Pharma; target of Rs 2000: Emkay Global Financial

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated November 06, 2025.

Sun Pharma breaks away from pure play generic companies in US

Sun Pharma’s revenues from specialty drugs surpassed generic medicines for the first time in the US

Buy Sun Pharma; target of Rs 1960: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated November 06, 2025.

Sun Pharma backs speciality play, lines up launches in US amid uncertainty over tariffs

Despite macro uncertainties, Sun Pharma has been bullish on its specialty pipeline and global expansion.

Sun Pharma Q2 steady — Should investors pop the stock pill?

While US generic sales would remain soft due to the reduced contribution of Revlimid, innovative medicine sales are expected to do well.

Sun Pharma net profit rises 2.6%YoY to Rs 3,118 crore in Q2FY26

Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.

Open to enhance manufacturing footprint in US: Sun Pharma

Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment for advanced skin cancer, in the US in the second half of FY26

Sun Pharma Q2 net profit up 3% at Rs 3,118 crore

New Delhi, Nov 5 Sun Pharmaceutical Industries on Wednesday posted a 2.56 per cent increase in its consolidated net profit to Rs 3,118 crore for the sec..

Sun Pharma Q2FY26 preview: Muted quarter likely as gRevlimid fades; watch margin trend and specialty ramp-up

With gRevlimid exclusivity nearing its end, the spotlight shifts to Sun Pharma’s specialty launches, domestic growth resilience, and management’s outlook on profitability for the second half of FY26.

USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?

The move is part of a broader push to onshore pharmaceutical production and reduce reliance on foreign suppliers, particularly from India and China.

Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive

Imported generics have so far managed to escape Trump’s glare likely due to their critical role in keeping US healthcare costs in check. However, Indian pharma is not waiting for the axe to fall, and experts say a multi-pronged defence strategy by key players is already in motion.

What does the new US tariff salvo mean for Indian pharma?

The diktat could be positive for local generic drug companies

Buyl Sun Pharma; target of Rs 1960: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1960 in its research report dated September 23, 2025.

How Sun Pharma’s diverse business is helping it overcome US FDA curbs on manufacturing plants

Exports from Halol manufacturing plant continue to be restricted

Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports

The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.

Buy Sun Pharma; target of Rs 1960: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated July 31, 2025.

Sun Pharma shares tumble 4% post-Q1 results; should you buy, sell or hold?

Brokerage Investec downgraded Sun Pharma shares by two notches to 'sell' while Choice Equity Broking gave an 'Add' rating

Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices

Trump's letters to 17 of the world’s biggest pharmaceutical majors has stated that companies should immediately lower charges for existing drugs, and furnish guarantee that future medicines be launched at par with what other countries are paying.

Sun Pharma Q1 Preview: Earnings likely to rise on India, specialty strength; margin impact from new launches

Sun Pharmaceuticals share price: India business is expected to grow 10 to 12 percent YoY, driven by volume gains, in-licensing deals, and new launches.

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

Net Sales are expected to increase by 5.2 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 13,628.1 crore, according to ICICI Securities.

Sun Pharma shares rise 2% as US patent settlement clears path for Leqselvi launch; Morgan Stanley remains overweight

Sun Pharma share price: Morgan Stanley projects Leqselvi sales at $61 million for FY26 and about $83 million for FY27.

Aurobindo Pharma, Dr Reddy's, Lupin, other pharma stocks tumble up to 3% amid tariff jitters

'A renewed push for 'Buy America' could complicate matters for low-margin generics, and any uptick in regulatory stringency may weigh on sentiment,' said an analyst.